

DAFTAR PUSTAKA

1. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toksoplasmosis. Vol. 25, *Clinical Microbiology Reviews*. 2012: 264–96.
2. Basri S. Toksoplasmosis Okular Kongenital. *J Kedokt Syiah Kuala*. 2017;17:133–9.
3. Arantes TEF, Silveira C, Holland GN, Muccioli C, Yu FEI, Jones JL, et al. Ocular Involvement Following Postnatally Acquired *Toxoplasma gondii* Infection in Southern Brazil: A 28-Year Experience. *Am J Ophthalmol* [Internet]. 2015;159:1002-12.
4. Cantor BL, Rapuano JC, Cioffi AG. Toxoplasmosis. In: *Basic and Clinical Science Course: Intraocular Inflammation and Uveitis*. Italy: American Academy of Ophthalmology; 2014: 226-34
5. Butler NJ, Furtado JM, Winthrop KL, Smith JR. Ocular toksoplasmosis II: Clinical Features, Pathology and Management. 2014;41(1):95–108.
6. Bosch-Driessen LEH, Berendschot TTJM, Ongkosuwito JV, Rothova A. Ocular Toksoplasmosis: Clinical Features and Prognosis of 154 Patients. *Ophthalmology*. 2002;109:869-78.
7. Guerina NG, Marquez L. Congenital toksoplasmosis: Clinical features and diagnosis. *UpToDate*. 2020:1–29.
8. Lindsay DS, Dubey JP. *Toxoplasma gondii*: The changing paradigm of congenital toxoplasmosis. *Parasitology*. 2011;138:1829–31.
9. Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis : a systematic review. 2013;501–8.
10. Boyer KM, Swisher CN, Roizen N, Stein L, Ph D, Withers S, et al. Eye Manifestations of Congenital Toxoplasmosis. *Am J Ophthalmol* [Internet]. 1996;122:309–24.
11. Irma Y, Nasronudin. Pathogenesis , Diagnostic and Management of. *Indones J Trop Infect Dis*. 2015;5(4):100-6.
12. Syrocot T, Review S, Toksoplasmosis C. Effectiveness of prenatal treatment for congenital toksoplasmosis: a meta-analysis of individual patients' data. *Lancet*. 2007;369(9556):115-22.
13. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital *Toxoplasma* infection. *Pediatrics*. 1980;66(5):767–74.
14. Fernandes Felix JP, Cavalcanti Lira RP, Grupenmacher AT, Assis Filho HLG de, Cosimo AB, Nascimento MA, et al. Long-term results of trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrent *Toxoplasma gondii* retinochoroiditis. *Am J Ophthalmol*. 2020;213:195–202.
15. Kim JS, Scott UI, Brown CG, Brown MM, Ho CA, Michael. Interventions for toxoplasma retinochoroiditis. *Ophthalmology*. 2013;120:371-8.
16. Nassaji M, Daraie G, Ghorbani R. Clinical feature and treatment outcome of active ocular toxoplasmosis in immunocompetent patients. *Asian Pac J Trop Med* [Internet]. 2010;3:571–3.
17. Guex-crosier Y. Update on the treatment of ocular toxoplasmosis. 2009;6:140–2.
18. McAuley JB. Congenital toksoplasmosis. *J Pediatric Infect Dis Soc*. 2014;3:30–5.



19. Nikhila KMS dan Cagri GB. Ocular Toxoplasmosis: A Refresher. *Eyenet Mag Retin Ophthalmic Pearls*. 2020;35–7.
20. Liu Q, Wang ZD, Huang SY, Zhu XQ. Diagnosis of toxoplasmosis and typing of *Toxoplasma gondii*. *Parasites and Vectors*. 2015;8:1–14.
21. Ikatan Dokter Anak Indonesia. Konsensus : Diagnosis dan Penatalaksanaan Infeksi toksoplasma dan CMV kongenital. 2019; 20-1
22. Do Couto Aleixo ALQ, De Oliveira RVC, Albuquerque MC, Biancardi AL, Land Curi AL, Benchimol EI, et al. Toxoplasmic retinochoroiditis: The influence of age, number of retinochoroidal lesions and genetic polymorphism for IFN- γ +874 T/A as risk factors for recurrence in a survival analysis. *PLoS One*. 2019;14:1–8.
23. Mets MB, Holfels E, Boyer KM, Swisher CN, Roizen N, Stein L, et al. Eye Manifestations of Congenital Toxoplasmosis. *Am J Ophthalmol*. 1996;122:309–24.
24. Pradhan E, Bhandari S, Gilbert RE, Stanford M. Antibiotics versus no treatment for toxoplasma retinochoroiditis. *Cochrane Database Syst Rev*. 2016;2016.
25. Soheilian M, Sadoughi M, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H, et al. Prospective Randomized Trial of Trimethoprim / Sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the Treatment of Ocular Toxoplasmosis. 2005;1876–82.
26. Nsiangani Lusambo N, Kaimbo Wa Kaimbo D, Ngoyi Mumba DM, de-la-Torre A. Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients. *BMC Ophthalmol*. 2023;23:1–8.
27. Garweg JG, Kieffer F, Mandelbrot L, Peyron F, Wallon M. Long-Term Outcomes in Children with Congenital Toxoplasmosis — A Systematic Review. 2022;1–21.
28. Villard O, Cimon B, L'Ollivier C, Fricker-Hidalgo H, Godineau N, Houze S, et al. Serological diagnosis of *Toxoplasma gondii* infection. Recommendations from the French National Reference Center for Toxoplasmosis. *Diagn Microbiol Infect Dis*. 2016;84:22–33.